Literature DB >> 12218296

The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure.

Timothy J O'Brien1, John B Beard, Lowell J Underwood, Kazushi Shigemasa.   

Abstract

CA 125 is a well-established marker for patients diagnosed with ovarian carcinoma. It is clearly elaborated in serous cystadenocarcinomas and less likely to be expressed in mucinous tumors. It has been 20 years since CA 125 was first recognized and it is only in recent years (the past 2) that some progress has been made toward cloning the gene, providing the basis for an understanding of the functional role of this molecule in embryonic development and neoplastic transformation. It is now clear that CA 125 is a large glycoprotein which is anchored to the epithelium by a transmembrane domain and is released into the extracellular space by enzymatic cleavage. Here, we describe a further major extension to the glycosylated extracellular amino terminal domain of this molecule. These additional data in association with our previous understanding of this molecule will provide the basis for our ability to understand the physiologic function of this molecule in biologic development and pathologic transformation. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218296     DOI: 10.1159/000064032

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  45 in total

1.  Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Authors:  Thapi Dharma Rao; Kay J Park; Peter Smith-Jones; Alexia Iasonos; Irina Linkov; Robert A Soslow; David R Spriggs
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-10

Review 2.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

3.  Characterization of a carbohydrate epitope defined by the monoclonal antibody H185: sialic acid O-acetylation on epithelial cell-surface mucins.

Authors:  Pablo Argüeso; Mika Sumiyoshi
Journal:  Glycobiology       Date:  2006-08-29       Impact factor: 4.313

4.  The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.

Authors:  Chanel Tyler; Arvinder Kapur; Mildred Felder; Jennifer A Belisle; Christine Trautman; Jennifer A A Gubbels; Joseph P Connor; Manish S Patankar
Journal:  Am J Reprod Immunol       Date:  2012-03-01       Impact factor: 3.886

5.  A binding domain on mesothelin for CA125/MUC16.

Authors:  Osamu Kaneko; Lucy Gong; Jingli Zhang; Johanna K Hansen; Raffit Hassan; Byungkook Lee; Mitchell Ho
Journal:  J Biol Chem       Date:  2008-12-15       Impact factor: 5.157

Review 6.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

7.  Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.

Authors:  Jennifer A Belisle; Sachi Horibata; Gubbels A A Jennifer; Sarah Petrie; Arvinder Kapur; Sabine André; Hans-Joachim Gabius; Claudine Rancourt; Joseph Connor; James C Paulson; Manish S Patankar
Journal:  Mol Cancer       Date:  2010-05-24       Impact factor: 27.401

8.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

Review 9.  The gastrointestinal mucus system in health and disease.

Authors:  Malin E V Johansson; Henrik Sjövall; Gunnar C Hansson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-12       Impact factor: 46.802

10.  CA125/MUC16 is dispensable for mouse development and reproduction.

Authors:  Dong-Joo Cheon; Ying Wang; Jian Min Deng; Zhen Lu; Lianchun Xiao; Chun-Ming Chen; Robert C Bast; Richard R Behringer
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.